vistusertib + palbociclib + fulvestrant

This is a combination therapy consisting of **vistusertib** (a dual mTORC1/2 inhibitor, also known as AZD2014), **palbociclib** (a selective CDK4/6 inhibitor, brand name Ibrance), and **fulvestrant** (a selective estrogen receptor degrader, brand name Faslodex). The rationale for the combination is that co-inhibition of the mTOR pathway (by vistusertib), the CDK4/6-Rb pathway (by palbociclib), and estrogen receptor signaling (by fulvestrant) may achieve a more profound and sustained inhibition of growth in estrogen receptor–positive (ER+) breast cancers, including those with resistance to endocrine therapy[1][5]. Preclinical studies and early clinical trials suggest that the triple regimen can induce tumor regression and long-term growth inhibition by convergently suppressing mTOR, RB-E2F, and estrogen receptor pathways, without marked increases in apoptosis over dual therapy[1].

Brand names

Ibrance + Faslodex

Other names

AZD2014 + Ibrance + Faslodex